Moderate

Toxic conjunctivitis (ocular surface medicamentosa, toxic keratoconjunctivitis)

Ocular surface · Ophthalmology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Direct toxic/irritant (± delayed hypersensitivity) damage to the ocular surface from chronic topical eye medications or their preservatives (especially benzalkonium chloride). Mimics allergic conjunctivitis; classically occurs in glaucoma or dry-eye patients on long-term multiple drops. DRAFT for clinician review.

Red flags

  • Large corneal epithelial erosion or ulceration
  • Pseudodendrites (rolled degenerated epithelium — may be confused with herpetic dendrites)
  • Decreased vision
  • Failure to resolve after stopping drops (reconsider infection or ocular cicatricial pemphigoid)

Assessment

Differential diagnosis

  • Seasonal/perennial allergic conjunctivitis
  • Vernal keratoconjunctivitis
  • Atopic keratoconjunctivitis
  • Giant papillary conjunctivitis
  • Hypersensitivity (allergic) reaction to a drop (occurs early vs toxic which is late)
  • Conjunctivitis medicamentosa (vasoconstrictor overuse)
  • Dry eye disease
  • Early ocular cicatricial pemphigoid

Investigations

  • History: symptoms worsened with continued drop use after initial improvement; tally all topical ocular meds, preservatives, duration
  • Slit-lamp: conjunctival hyperemia, chemosis, papillary reaction, punctate epithelial staining on fluorescein, erosions
  • Schirmer test, tear break-up time, lissamine green staining
  • Patch testing rarely helpful (local reaction)
  • Diagnosis confirmed when stopping the offending drop resolves it

Management

  • Identify and stop as many topical agents/preservatives as feasible
  • Switch to preservative-free formulation or an oral alternative
  • Cold compresses + preservative-free artificial tears/ointment
  • Ophthalmology monitoring (rule out an infectious cause)
  • Topical corticosteroid for moderate–severe cases (ophthalmologist) with IOP monitoring

Drugs & doses

Discontinue the offending drop(s); substitute a preservative-free formulation or oral equivalent where possible.
Preservative-free artificial tears/ointment + cold compresses — symptomatic relief.
Topical corticosteroid for moderate–severe disease (OPHTHALMOLOGIST) — short course, typically 2–6 weeks, 1–4×/day (1–2×/day in mild cases). Options: loteprednol etabonate 0.5% gel or 0.38%, loteprednol ointment (BAK-free), prednisolone sodium phosphate 0.5% (BAK-free), or a preservative-free steroid. In glaucoma / steroid-IOP risk, prefer loteprednol (and gel/0.38% over suspension). Monitor intraocular pressure.

Disposition

Discharge after stopping the offending agent, with ophthalmology follow-up. Refer to a corneal specialist if dry eye versus toxic conjunctivitis is unclear or if topical steroids are required.

Complications & pitfalls

  • Corneal erosion/ulceration
  • Visual dysfunction
  • Chronic ocular surface disease
  • Steroid-induced raised intraocular pressure

Exam pearls

  • Suspect in any red eye on chronic preservative-containing drops — especially glaucoma patients on multiple drops
  • The history 'improved, then got worse with continued use' is the tell
  • Benzalkonium chloride is the usual culprit preservative
  • Not allergic — patch testing is usually unhelpful

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.